ADMA Q4 2022 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M+89.4% YoY

Gross Profit

$14M28.4% margin

Operating Income

-$6M-12.1% margin

Net Income

-$12M-24.5% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+21.6%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$11M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$348M

Total Liabilities

$196M

Stockholders' Equity

$152M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$26M	+89.4%
Gross Profit	$14M	$4M	+303.7%
Operating Income	-$6M	-$13M	+54.1%
Net Income	-$12M	-$17M	+26.5%

Revenue Segments

Product Revenue

$50M100%

License Revenue

$35,7090%

Geographic Segments

United States

$50M100%